ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

LTS Ladenburg Thalmann Financial Services Inc

3.49
0.00 (0.00%)
Last Updated: 01:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type
Ladenburg Thalmann Financial Services Inc AMEX:LTS AMEX Common Stock
  Price Change % Change Share Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 3.49 0 01:00:00

Ladenburg Thalmann Appoints Christopher S. James, M.D. as Managing Director, Equity Research Covering Biotechnology

06/01/2017 1:00pm

Business Wire


Ladenburg Thalmann Finan... (AMEX:LTS)
Historical Stock Chart


From Apr 2019 to Apr 2024

Click Here for more Ladenburg Thalmann Finan... Charts.

Ladenburg Thalmann Financial Services Inc. (NYSE MKT: LTS, LTS PrA), announced today that Christopher S. James, M.D. has been appointed as Managing Director, Equity Research at Ladenburg Thalmann & Co. Inc. ("Ladenburg") covering biotechnology. Dr. James is based in Ladenburg’s New York office.

David Rosenberg, Co-President and Chief Executive Officer of Ladenburg Thalmann & Co. Inc., said, “We are delighted to welcome Chris to Ladenburg. Chris has differentiated himself in the market with his experience covering a wide range of biotechnology companies and unique background as a physician, specifically as a neurosurgeon. We look forward to his insights and expertise as the newest member of our biotechnology team.”

Dr. James joins Ladenburg with more than a decade of experience as a biotechnology analyst focused on small, mid and large-cap companies across multiple therapeutic areas. Most recently, he served as Senior Biotechnology Equity Research Analyst at FBR Capital Markets. Prior to joining FBR, Dr. James held Senior Analyst roles at Brinson Patrick Securities, MLV & Co. and Rodman & Renshaw. Dr. James also previously served as the first Chief Medical Officer of Retrophin Inc., a public biotechnology company focused on developing orphan drug therapies to treat rare diseases, and managed business development at Daiichi Sankyo, Inc.

Dr. James received a Medical Degree from the Yale University School of Medicine and a Bachelor of Science in Biology from Cornell University. He is a licensed physician with training in general surgery, neurology and neurosurgery from Weill-Cornell New York Hospital and Memorial Sloan Kettering Cancer Center.

About Ladenburg

Ladenburg Thalmann Financial Services Inc. (NYSE MKT: LTS, LTS PrA) is a publicly-traded diversified financial services company based in Miami, Florida. Ladenburg’s subsidiaries include industry-leading independent broker-dealer firms Securities America, Inc., Triad Advisors, Inc., Securities Service Network, Inc., Investacorp, Inc. and KMS Financial Services, Inc., as well as Premier Trust, Inc., Ladenburg Thalmann Asset Management Inc., Highland Capital Brokerage, Inc., a leading independent life insurance brokerage company, and Ladenburg Thalmann & Co. Inc., an investment bank which has been a member of the New York Stock Exchange for over 135 years. The company is committed to investing in the growth of its subsidiaries while respecting and maintaining their individual business identities, cultures, and leadership. For more information, please visit www.ladenburg.com.

Sard Verbinnen & CoPaul Caminiti/Emily Deissler/Benjamin Spicehandler212-687-8080

1 Year Ladenburg Thalmann Finan... Chart

1 Year Ladenburg Thalmann Finan... Chart

1 Month Ladenburg Thalmann Finan... Chart

1 Month Ladenburg Thalmann Finan... Chart

Your Recent History

Delayed Upgrade Clock